Wong I C
David-Lewis Centre for Epilepsy, Warford, Near Alderley Edge, Cheshire, UK.
Epilepsy Res. 1995 Jul;21(3):227-30. doi: 10.1016/0920-1211(95)00022-3.
Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.
氨己烯酸（VGB）是一种有效的附加抗癫痫药物。主要的严重药物不良反应（ADR）是行为和精神障碍。本研究不支持既往有行为和精神特征病史会增加行为/精神性ADR风险的观点（相对风险1.23，95%置信区间0.57 - 2.66，P = 0.61）。结果表明，低起始剂量的氨己烯酸不会降低精神和行为性ADR的风险（P = 0.31），也不能预防更明显的精神病性反应的发生。
